Caplin Point stock receives USFDA to enter $67M US sales segment

Caplin Point’s subsidiary secured USFDA approval for Sodium Phosphates Injection, entering a $67 million US sales category. The approval strengthens its sterile injectable portfolio and regulated market footprint. With 51 ANDA approvals out of 54 filings and a 55+ product pipeline, the company continues expanding in the US generics space, supporting long-term growth prospects.